Patents by Inventor Richard G. Wilde

Richard G. Wilde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160199357
    Abstract: The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
    Type: Application
    Filed: February 16, 2016
    Publication date: July 14, 2016
    Inventors: Neil ALMSTEAD, Guangming CHEN, Samit HIRAWAT, Peter Seongwoo HWANG, Gary M. KARP, Paul KENNEDY, Langdon MILLER, Young-Choon MOON, Hongyu REN, James J. TAKASUGI, Ellen M. WELCH, Richard G. WILDE
  • Patent number: 9289398
    Abstract: The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: March 22, 2016
    Assignee: PTC Therapeutics, Inc.
    Inventors: Neil Almstead, Guangming Chen, Samit Hirawat, Peter Seongwoo Hwang, Gary M. Karp, Langdon Miller, Young-Choon Moon, Hongyu Ren, James J. Takasugi, Ellen M. Welch, Richard G. Wilde, Paul Kennedy
  • Patent number: 8334313
    Abstract: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: December 18, 2012
    Assignee: PTC Therapeutics, Inc.
    Inventors: Richard G. Wilde, James J. Takasugi, Seongwoo Hwang, Ellen M. Welch, Guangming Chen
  • Publication number: 20110130397
    Abstract: Provided herein are compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase, including compositions and dosage forms comprising the compounds. Further provided herein are methods for preventing or inhibiting bacterial proliferation as well as methods for preventing, treating, and/or managing a bacterial infection using such compounds and compositions.
    Type: Application
    Filed: September 21, 2007
    Publication date: June 2, 2011
    Inventors: Soongyu Choi, Arthur Branstrom, Scott A. Gothe, Richard Lipman, Tamil Arasu, Richard G. Wilde
  • Publication number: 20110130391
    Abstract: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
    Type: Application
    Filed: December 29, 2010
    Publication date: June 2, 2011
    Inventors: Richard G. Wilde, James J. Takasugi, Seongwoo Hwang, Ellen M. Welch, Guangming Chen
  • Patent number: 7902241
    Abstract: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: March 8, 2011
    Assignee: PTC Therapeutics, Inc.
    Inventors: Richard G. Wilde, James J. Takasugi, Seongwoo Hwang, Ellen M. Welch, Guangming Chen
  • Publication number: 20110046136
    Abstract: The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
    Type: Application
    Filed: March 29, 2007
    Publication date: February 24, 2011
    Applicant: THERAPEUTICS, INC.
    Inventors: Neil G. Almstead, Guangming Chen, Hirawat Samit, Peter Seongwoo Hwang, Gary M. Karp, Langdon Miller, Young-Choon Moon, Hongyu Ren, James J. Takasugi, Ellen M. Welch, Richard G. Wilde, Paul Kennedy
  • Patent number: 7763656
    Abstract: Novel acetylamino benzoic acid compounds, methods of using and pharmaceutical compositions comprising an acetylamino benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: July 27, 2010
    Assignees: PTC Therapeutics, Inc., Amgen Inc.
    Inventors: Richard G. Wilde, Ellen M. Welch, James Jan Takasugi, Neil G. Almstead, Steven Marc Rubenstein, Holger Beckmann
  • Publication number: 20100069380
    Abstract: Provided herein are compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase, including compositions and dosage forms comprising the compounds. Further provided herein are methods for screening and identifying compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase. In particular, provided herein are assays for the identification of compounds that inhibit or reduce the activity of a bacterial peptidyl tRNA hydrolase. The methods provided herein provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for preventing, treating, and managing a bacterial infection or one or more symptoms thereof. Further provided herein are methods for preventing or inhibiting bacterial proliferation as well as methods for preventing, treating, and/or managing a bacterial infection using such compounds and compositions.
    Type: Application
    Filed: September 21, 2007
    Publication date: March 18, 2010
    Inventors: Soongyu Choi, Arthur Branstrom, Scott A. Gothe, Richard Lipman, Tamil Arasu, Richard G. Wilde
  • Patent number: 7449570
    Abstract: The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: November 11, 2008
    Assignees: PTC Therapeutics, Inc., Amgen Inc.
    Inventors: Richard G. Wilde, Neil G. Almstead, Ellen M. Welch, Holger Beckmann
  • Publication number: 20080275233
    Abstract: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
    Type: Application
    Filed: June 17, 2008
    Publication date: November 6, 2008
    Inventors: Richard G. Wilde, James J. Takasugi, Seongwoo Hwang, Ellen M. Welch, Guangming Chen
  • Patent number: 7405233
    Abstract: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: July 29, 2008
    Assignee: PTC Therapeutics, Inc.
    Inventors: Richard G. Wilde, James J. Takasugi, Seongwoo Hwang, Ellen M. Welch, Guangming Chen
  • Patent number: 7291603
    Abstract: The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
    Type: Grant
    Filed: July 22, 2003
    Date of Patent: November 6, 2007
    Assignee: PTC Therapeutics, Inc.
    Inventors: Richard G. Wilde, Paul D. Kennedy, Neil G. Almstead, Ellen M. Welch, James J. Takasugi, Westley J. Friesen
  • Patent number: 7247741
    Abstract: Novel acetylamino benzoic acid compounds, methods of using and pharmaceutical compositions comprising an acetylamino benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: July 24, 2007
    Assignees: PTC Therapeutics, Inc., Amgen Inc.
    Inventors: Richard G. Wilde, Ellen M. Welch, James Jan Takasugi, Neil G. Almstead, Steven Marc Rubenstein, Holger Beckmann
  • Patent number: 7045529
    Abstract: Provided herein are compounds of the formula (I): as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by execssive CRF expression. These include, for example: affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: May 16, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard G. Wilde, Rajagopal Bakthavatchalam, James P. Beck, Argyrios Arvanitis
  • Patent number: 7026317
    Abstract: The present invention relates to pyrazolotriazines according to formula (I) and stereoisomers, isomers and salts thereof wherein R1-R5 are selected from certain alkyl, aryl and heteroaryl species as defined in the specification wherein all of the compounds are useful as CRF antagonists and are thus useful in the treatment of neurological disorders as well as a multitude of other CRF associated diseases or conditions.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: April 11, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul J. Gilligan, Richard G. Wilde
  • Patent number: 6960583
    Abstract: The present invention relates to pyrazolotriazines according to formula (I) and stereoisomers, isomers and salts thereof wherein R1-R5 are selected from certain alkyl, aryl and heteroaryl species as defined in the specification wherein all of the compounds are useful as CRF antagonists and are thus useful in the treatment of neurological disorders as well as a multitude of other CRF associated diseases or conditions.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: November 1, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul J. Gilligan, Richard G. Wilde
  • Patent number: 6958341
    Abstract: The present invention relates to pyrazolopyrimidines according to formula (I) and stereoisomers, isomers and salts thereof wherein R1-R5 are selected from certain alkyl, aryl and heteroaryl species as defined in the specification wherein all of the compounds are useful as CRF antagonists and are thus useful in the treatment of neurological disorders as well as a multitude of other CRF associated diseases or conditions.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: October 25, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard G. Wilde, Paul J. Gilligan
  • Publication number: 20040229887
    Abstract: Provided herein are compounds of the formula (I): 1
    Type: Application
    Filed: December 15, 2000
    Publication date: November 18, 2004
    Inventors: Richard G. Wilde, Rajagopal Bakthavatchalam, James P. Beck, Argyrios Arvanitis
  • Publication number: 20040176376
    Abstract: The present invention relates to pyrazolotriazines according to formula (I) 1
    Type: Application
    Filed: March 18, 2004
    Publication date: September 9, 2004
    Applicant: Bristol-Myers Squibb Pharma Company
    Inventors: Paul J. Gilligan, Richard G. Wilde